These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 27745751)

  • 1. Province-Wide Review of Pediatric Shiga Toxin-Producing Escherichia coli Case Management.
    Freedman SB; Eltorki M; Chui L; Xie J; Feng S; MacDonald J; Dixon A; Ali S; Louie M; Lee BE; Osterreicher L; Thull-Freedman J
    J Pediatr; 2017 Jan; 180():184-190.e1. PubMed ID: 27745751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bloody Diarrhea and Shiga Toxin-Producing Escherichia coli Hemolytic Uremic Syndrome in Children: Data from the ItalKid-HUS Network.
    Ardissino G; Vignati C; Masia C; Capone V; Colombo R; Tel F; Daprai L; Testa S; Dodaro A; Paglialonga F; Luini M; Brigotti M; Picicco D; Baldioli C; Pagani F; Ceruti R; Tommasi P; Possenti I; Cresseri D; Consonni D; Montini G; Arghittu M;
    J Pediatr; 2021 Oct; 237():34-40.e1. PubMed ID: 34197890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relative nephroprotection during Escherichia coli O157:H7 infections: association with intravenous volume expansion.
    Ake JA; Jelacic S; Ciol MA; Watkins SL; Murray KF; Christie DL; Klein EJ; Tarr PI
    Pediatrics; 2005 Jun; 115(6):e673-80. PubMed ID: 15930195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infections in pediatric postdiarrheal hemolytic uremic syndrome: factors associated with identifying shiga toxin-producing Escherichia coli.
    Mody RK; Luna-Gierke RE; Jones TF; Comstock N; Hurd S; Scheftel J; Lathrop S; Smith G; Palmer A; Strockbine N; Talkington D; Mahon BE; Hoekstra RM; Griffin PM
    Arch Pediatr Adolesc Med; 2012 Oct; 166(10):902-9. PubMed ID: 22869280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A role for fosfomycin treatment in children for prevention of haemolytic-uraemic syndrome accompanying Shiga toxin-producing Escherichia coli infection.
    Tajiri H; Nishi J; Ushijima K; Shimizu T; Ishige T; Shimizu M; Tanaka H; Brooks S
    Int J Antimicrob Agents; 2015 Nov; 46(5):586-9. PubMed ID: 26391378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interventions for Shiga toxin-producing Escherichia coli gastroenteritis and risk of hemolytic uremic syndrome: A population-based matched case control study.
    Myojin S; Pak K; Sako M; Kobayashi T; Takahashi T; Sunagawa T; Tsuboi N; Ishikura K; Kubota M; Kubota M; Igarashi T; Morioka I; Miyairi I
    PLoS One; 2022; 17(2):e0263349. PubMed ID: 35120154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is Shigatoxin 1 protective for the development of Shigatoxin 2-related hemolytic uremic syndrome in children? Data from the ItalKid-HUS Network.
    Ardissino G; Possenti I; Vignati C; Daprai L; Capone V; Brigotti M; Luini MV; Consonni D; Montini G
    Pediatr Nephrol; 2020 Oct; 35(10):1997-2001. PubMed ID: 32734345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unusual severe case of hemolytic uremic syndrome due to Shiga toxin 2d-producing E. coli O80:H2.
    Wijnsma KL; Schijvens AM; Rossen JWA; Kooistra-Smid AMDM; Schreuder MF; van de Kar NCAJ
    Pediatr Nephrol; 2017 Jul; 32(7):1263-1268. PubMed ID: 28343354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An epidemiologic surveillance of Shiga-like toxin-producing Escherichia coli infection in Argentinean children: risk factors and serum Shiga-like toxin 2 values.
    López EL; Contrini MM; Glatstein E; Ayala SG; Santoro R; Ezcurra G; Teplitz E; Matsumoto Y; Sato H; Sakai K; Katsuura Y; Hoshide S; Morita T; Harning R; Brookman S
    Pediatr Infect Dis J; 2012 Jan; 31(1):20-4. PubMed ID: 21829137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case-management protocol for bloody diarrhea as a model to reduce the clinical impact of Shiga toxin-producing Escherichia coli infections. Experience from Southern Italy.
    Loconsole D; Giordano M; Laforgia N; Torres D; Santangelo L; Carbone V; Parisi A; Quarto M; Scavia G; Chironna M;
    Eur J Clin Microbiol Infect Dis; 2020 Mar; 39(3):539-547. PubMed ID: 31776873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical features, therapeutic interventions and long-term aspects of hemolytic-uremic syndrome in Norwegian children: a nationwide retrospective study from 1999-2008.
    Jenssen GR; Vold L; Hovland E; Bangstad HJ; Nygård K; Bjerre A
    BMC Infect Dis; 2016 Jun; 16():285. PubMed ID: 27297224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli in children: incidence, risk factors, and clinical outcome.
    Ylinen E; Salmenlinna S; Halkilahti J; Jahnukainen T; Korhonen L; Virkkala T; Rimhanen-Finne R; Nuutinen M; Kataja J; Arikoski P; Linkosalo L; Bai X; Matussek A; Jalanko H; Saxén H
    Pediatr Nephrol; 2020 Sep; 35(9):1749-1759. PubMed ID: 32323005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperhydration to Improve Kidney Outcomes in Children with Shiga Toxin-Producing E. coli Infection: a multinational embedded cluster crossover randomized trial (the HIKO STEC trial).
    Freedman SB; Schnadower D; Estes M; Casper TC; Goldstein SL; Grisaru S; Pavia AT; Wilfond BS; Metheney M; Kimball K; Tarr PI;
    Trials; 2023 May; 24(1):359. PubMed ID: 37245030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting Hemolytic Uremic Syndrome and Renal Replacement Therapy in Shiga Toxin-producing Escherichia coli-infected Children.
    McKee RS; Schnadower D; Tarr PI; Xie J; Finkelstein Y; Desai N; Lane RD; Bergmann KR; Kaplan RL; Hariharan S; Cruz AT; Cohen DM; Dixon A; Ramgopal S; Rominger A; Powell EC; Kilgar J; Michelson KA; Beer D; Bitzan M; Pruitt CM; Yen K; Meckler GD; Plint AC; Bradin S; Abramo TJ; Gouin S; Kam AJ; Schuh A; Balamuth F; Hunley TE; Kanegaye JT; Jones NE; Avva U; Porter R; Fein DM; Louie JP; Freedman SB;
    Clin Infect Dis; 2020 Apr; 70(8):1643-1651. PubMed ID: 31125419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Shiga Toxin-Producing Escherichia coli Infection, Antibiotics, and Risk of Developing Hemolytic Uremic Syndrome: A Meta-analysis.
    Freedman SB; Xie J; Neufeld MS; Hamilton WL; Hartling L; Tarr PI; ; Nettel-Aguirre A; Chuck A; Lee B; Johnson D; Currie G; Talbot J; Jiang J; Dickinson J; Kellner J; MacDonald J; Svenson L; Chui L; Louie M; Lavoie M; Eltorki M; Vanderkooi O; Tellier R; Ali S; Drews S; Graham T; Pang XL
    Clin Infect Dis; 2016 May; 62(10):1251-1258. PubMed ID: 26917812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Shiga toxin-induced haemolytic uraemic syndrome and the role of antibiotics: a global overview.
    Kakoullis L; Papachristodoulou E; Chra P; Panos G
    J Infect; 2019 Aug; 79(2):75-94. PubMed ID: 31150744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of Shiga toxin-producing Escherichia coli infections.
    Davis TK; McKee R; Schnadower D; Tarr PI
    Infect Dis Clin North Am; 2013 Sep; 27(3):577-97. PubMed ID: 24011831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of diarrhea-associated hemolytic uremic syndrome in children.
    Iijima K; Kamioka I; Nozu K
    Clin Exp Nephrol; 2008 Feb; 12(1):16-9. PubMed ID: 18175052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence and etiology of hemolytic-uremic syndrome in children in Norway, 1999-2008--a retrospective study of hospital records to assess the sensitivity of surveillance.
    Jenssen GR; Hovland E; Bjerre A; Bangstad HJ; Nygard K; Vold L
    BMC Infect Dis; 2014 May; 14():265. PubMed ID: 24884396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome 10 years after Shiga toxin-producing E. coli (STEC)-associated hemolytic uremic syndrome: importance of long-term follow-up.
    Rosales A; Kuppelwieser S; Giner T; Hofer J; Riedl Khursigara M; Orth-Höller D; Borena W; Cortina G; Jungraithmayr T; Würzner R;
    Pediatr Nephrol; 2024 Aug; 39(8):2459-2465. PubMed ID: 38589699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.